For centuries, placebos have been used to treat pain. They also represent a pillar of clinical research, wherein the double-blind placebo-controlled study stands as the gold standard for establishing the efficacy of pain treatments. Although legitimate ethical concerns have been voiced regarding the use of placebos in clinical practice [3] , evidence suggests that clinicians continue to use placebos widely to manage both acute and chronic pain syndromes [1] .
Despite this widespread use of placebos in both clinical and research settings, their role in the pain experience remains poorly understood and consensus does not yet exist surrounding their appropriate and ethical application. The recently published study by Chung et al. [1] is the first paper to directly address an important question: What happens if patients are informed that their pain was alleviated after they received a placebo treatment? Traditionally, pain researchers and clinicians, reticent to inform individuals of their personal placebo response, have maintained an implicit ''Don't ask, don't tell" policy. This stance is based on the concern that revealing to the patient that he/she received a placebo might engender a sense of mistrust and betrayal in the patient toward the physician, thereby undermining the physician/patient relationship and potentially interfering with future efforts to manage pain [1] .
Intriguing, and contrary to expectation, is the Chung et al. [1] finding that disclosure of an earlier positive response to a placebo does not alter healthy volunteers' likelihood of responding positively to subsequent placebo treatment (Study 2). Chung et al.
[1] also demonstrated, in irritable bowel syndrome patients (Study 1), that informing patients that their clinical pain had initially responded to a placebo resulted in slightly increased frustration but had minimal effect on other moods such as anger, fear, anxiety, or depression and on patients' reports of the likeability of and trust in the experimenter. Taken together, the seminal methods and findings of Chung et al. [1] have important implications for understanding, revealing, and harnessing the potential therapeutic effects of placebos in pain research and clinical practice.
Research
Two major features of the research methods used by Chung et al. [1] likely contributed to the magnitude and persistence of the placebo response. First, both studies incorporated conditioning trials in which a placebo cream was repeatedly paired with sequentially lower levels of pain stimuli, to induce the expectation that pain relief would accompany administration of the placebo cream. Conditioning trials are used in many placebo studies; evidence suggests that placebo effects obtained via conditioning are unusually resistant to extinction (e.g., [2, 4] ). A worthy direction for future research, especially if placebos are to be incorporated into clinical practice, would be to determine whether a threshold number of conditioning trials is needed to ensure that a placebo response persists after an individual learns that he/she responded favorably to a placebo. Second, the instructions used by Chung et al. [1] differ from those typically used in double-blind, placebo-controlled clinical trials. Specifically, the investigators told placeboreceivers that ''the agent that had just been given is known to significantly reduce pain in some people". This instruction diverges from that typically delivered to patients at the outset of a double-blind placebo-controlled study, where participants are typically informed that they have a 50/50 chance of receiving a real pain medication or a placebo. An important direction for future research would be to examine and compare the impact of different instructional sets on development of the placebo effect, and the placebo effects' persistence after
